September 4, 2014 | The English High Court ruled in support of Israeli company Teva Pharmaceutical Industries in their case against Astra-Zeneca, a multi-national pharmaceutical and biologics company. According to the court, Astra-Zeneca will not be allowed to change their patent for the smart indication of Symbicort in order to facilitate Teva’s upcoming European launch of is asthma treatment DuoResp Spiromax, using Teva’s Spiromax technology.
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts

Israeli Startup Tests Cancer Treatment With Pharma Giant
February 07, 2023

EU Awards $5M To Greenhouse Solar Panel Project
February 07, 2023

Israel Builds Super-Advanced Children’s Hospital
February 07, 2023

Two Thirds Of Hi-Tech Workers In Israel Are Men, Study Finds
February 06, 2023
Facebook comments